Moreover, aberrant expression of TROP2 significantly correlates with poor overall survival and disease-free survival, suggesting that TROP2 can be considered an independent prognostic predictor for HNSCC patients. This evidence concerns the gene TACSTD2 and head and neck squamous cell carcinoma.